摘要
研究表皮生长因子受体(EGFR)和转化生长因子α(TGF-α)与卵巢癌发生发展的关系.方法:用免疫组化ABC方法检测了EGFR,TGF-α,表皮生长因子(EGF)在72例卵巢肿瘤及正常卵巢组织中的表达情况.结果:TGF-α在卵巢癌中的检出率为71.05%,在良性肿瘤、交界性肿瘤和正常卵巢组织中的检出率分别为3.00%,58.33%%及41.67%,各组与卵巢癌组间均有显著差异(PM0.05).EGFR在上述4组中的检出率分别为76.32%,40.00%,66.67%和41.67%,除交界性肿瘤组外,其余各组与卵巢癌组相比差异显著(P<0.05).在不同临床分期的卵巢癌中,TGF-α和EGFR的检出率分别为Ⅰ期:50%和50%,Ⅱa,b期:70.59%和76.47%,Ⅱc-Ⅳ期:84.62%和92.31%,可以看出TGF-α和EGFR在临床分期越晚的卵巢癌中,其检出率越高,且多数组间存在显著差异(P<0.05).EGF在上述各类组织中极少表达.结论:TGF-α和EGFR在卵巢肿瘤中有高水平的表达,且恶性程度越高,表达率越高,提示TGF-α/EGFR自分泌系统在卵巢癌的发生发展中起着重要的作用,而EGF/EGFR这一系统可能在卵巢癌中不发挥作用.
To study the relationship between epidermal growth factor receptor (EGFR), TGF-α,EGF and occurrence and development of ovarian cancer. Methods: Using ABC immunohistochemistry method.we investigated the expression of EGFR, TGF-α, EGF in 72 cases of ovarian neoplasm. Results: The positive rate of TGF-α in ovarian cancer, benign tumor, borderline tumor and normal ovarian tissue was 71. 05%,30. 00 %, 58. 33 % and 41. 6% respectively. There was significant difference between ovarian cancer group and other groups (P<0. 05). The positive rate of EGFR in above groups was 76. 32%, 40. 00%, 66. 67% and 41. 67 % respectively. Except borderline tumor groyp, the significant difference was found between ovarian cancer and other groups(P<0. 05). In different clinical phases of the ovarian cancer,the detectable rate of TGF-α and EGFR was that phase Ⅰ: 50. 00% and 50. 00%,phase Ⅱ a, b: 70. 59% and 76. 47%,phase Ⅱ c~Ⅳ:84. 62% and 92. 31 %, respectively. The higher the clinical phase was,the higher the positive rate was detected.Significant difference was found amongmost groups (P<0. 05). Very low positive rate of EGF was detected in these kinds of tissues. Conclusions: TGF-α and EGFR autocrine mechanism play an important role in the occurrence and development of ovarian cancer, but EGF and EGFR doesn' t.
出处
《第四军医大学学报》
1997年第6期557-559,共3页
Journal of the Fourth Military Medical University
关键词
卵巢肿瘤
表皮生长因子
EGFR
免疫组织化学
ovarian neoplasm epidermal growth factor epidermal growth factor receptor transforming growth factor-α immunohistochemistry